Table 1.
In- and exclusion criteria.
Fig 1.
Consort flow chart.
Table 2.
Baseline Characteristics.
Fig 2.
Mean change in BCVA from baseline.
Mean change in BCVA per group. A mixed linear model was used for this graph. This type of analysis shows a mean gain of 5.9 letters in the bevacizumab group and a mean gain of 6.7 letters in the ranibizumab group (p = 0.56).
Fig 3.
Mean change in central retinal thickness.
Effect of bevacizumab (n = 161, blue) versus ranbizumab (n = 166, red) on the change of retinal thickness over time. Data are presented as mean ±95% CI. A mixed linear model was used for this graph.
Table 3.
Outcome Measures at 12 months.
Table 4.
Serious adverse events.
Table 5.
Adverse events by organ system.